Testosterone + NPP + Primobolan
Risk: HighSupport lean muscular accretion and nitrogen retention while moderating estrogenic water retention through balanced androgenic and non-aromatizing anabolic signaling.

Composition: 3 Steroids
Overview
Target Audience Assumption: This stack is structured for intermediate adult male users with prior experience administering injectable anabolic-androgenic steroids (AAS), managing testosterone aromatization, and interpreting serial endocrine and cardiovascular bloodwork. Prior cycle experience alone does not establish physiological tolerance, justify dose escalation, or define a minimum required total dose. Core Architecture & Formulation Assumptions: Because specific esters and routes are omitted from the base compound labels, this protocol explicitly assumes intramuscular Testosterone Enanthate as the physiological androgen and estrogen precursor base, intramuscular Nandrolone Phenylpropionate (NPP) as the shorter-estered 19-norandrogen anabolic agent (linked to the general nandrolone CMS profile while preserving phenylpropionate pharmacokinetics in scheduling), and intramuscular Primobolan Depot (Methenolone Enanthate) as the non-aromatizing 5-alpha-reduced dihydrotestosterone (DHT) derivative (distinct from oral methenolone acetate). In reported practice, this trio is selected for lean tissue accretion with lower extracellular fluid retention than nandrolone decanoate cycles, paired with a defined clearance transition and post-cycle therapy (PCT) for users discontinuing exogenous androgens.
Why this stack works
Ester Alignment & Injection Cadence: Nandrolone phenylpropionate (NPP) exhibits a shorter elimination half-life (~2.5 to 4.5 days) than nandrolone decanoate, requiring administration at least three times weekly to avoid sharp serum fluctuations. Although Testosterone Enanthate and Methenolone Enanthate possess longer half-lives (~4.5 to 7 days), splitting all three compounds across the same Monday/Wednesday/Friday schedule stabilizes serum hormone levels, keeps single-injection oil volume manageable (as both NPP and Primobolan Depot are conventionally formulated at 100 mg/mL), and allows the phenylpropionate ester of nandrolone extra clearance margin while the enanthate esters decay during the two-week pre-PCT transition window. Endocrine Balance & Estradiol ($E_2$) Modulation: Testosterone converts via aromatase (CYP19A1) into estradiol ($E_2$), which is essential for vascular endothelium function, lipid homeostasis, bone mineralization, central nervous system health, and male libido/erectile function. NPP aromatizes at roughly 20% the rate of testosterone, whereas Primobolan does not aromatize. Crucially, both early clinical observations and widespread user bloodwork indicate that methenolone (Primobolan) frequently acts as a competitive aromatase inhibitor or reduces circulating estradiol relative to a given testosterone dose. There is no universal safe Testosterone-to-Primobolan ratio established by controlled research because individual aromatase expression and adiposity vary substantially. Setting Testosterone Enanthate modestly higher than Methenolone Enanthate reduces the risk of inadvertently suppressing estradiol into a deficient range (crashed $E_2$), which manifests as arthralgia, anhedonia, sexual dysfunction, and accelerated dyslipidemia. Consequently, synthetic aromatase inhibitors (AIs) are categorized as strictly conditional on lab-confirmed hyperestrogenemia with clinical symptoms rather than routine prophylaxis. Progestogenic, Prolactin & Androgenic (DHT vs. DHN) Interactions: NPP binds and activates the progesterone receptor. Progestogenic signaling sensitizes mammary tissue to estradiol and can stimulate pituitary lactotrophs to elevate prolactin, particularly when estradiol is poorly controlled. In reported practice, Primobolan's restraining effect on serum estradiol helps mitigate estradiol-driven prolactin elevation and gynecomastia risk from NPP without mandatory AI administration. Additionally, in 5-alpha-reductase-active tissues, testosterone converts to potent dihydrotestosterone (DHT), whereas nandrolone converts to dihydronandrolone (DHN), a markedly weaker androgen receptor agonist. While observational practice suggests that co-administering Testosterone and a DHT derivative like Primobolan helps offset DHN-mediated androgenic insufficiency (often implicated in nandrolone-associated sexual dysfunction), controlled clinical trials validating a protective ratio are absent. Furthermore, 5-alpha-reductase inhibitors (finasteride, dutasteride) must be avoided because blocking 5-alpha-reductase prevents nandrolone from converting to weaker DHN—paradoxically intensifying nandrolone's androgenic adverse effects—while offering zero protection against already 5-alpha-reduced Primobolan. Cumulative Toxicity & Ancillary Limitations: All three steroids additively suppress the hypothalamic-pituitary-testicular axis (HPTA), with NPP's dual androgenic and progestogenic negative feedback creating deeper gonadotropin inhibition. The combination also produces additive reductions in HDL cholesterol (strongly driven by DHT-derived Primobolan), increases in ApoB/LDL cholesterol, stimulation of erythropoiesis (elevating hematocrit and blood viscosity), and potential blood pressure elevation. Supportive agents (hCG, omega-3s, antihypertensives, vitamin B6/P5P, or SERMs) target specific downstream biomarkers, but adding ancillary drugs does not automatically correct or make safe an excessive cumulative steroid load.
Protocol timeline
4 phases · 22 weeks total
Timeline shows the 22-week cycle. Bars overlap when phases run concurrently. Click a bar to jump to its detail card.
The interactive timeline loads here. Phase details are available below.
Core Anabolic-Steroid Schedule (Intramuscular, Mon/Wed/Fri Split): • Testosterone Enanthate: 100 mg per administration intramuscularly 3 times weekly (Monday, Wednesday, Friday), for a per-compound weekly total of 300 mg/week. • Nandrolone Phenylpropionate (NPP): 80 mg per administration intramuscularly 3 times weekly (Monday, Wednesday, Friday), for a per-compound weekly total of 240 mg/week. • Primobolan Depot (Methenolone Enanthate): 80 mg per administration intramuscularly 3 times weekly (Monday, Wednesday, Friday), for a per-compound weekly total of 240 mg/week. • Combined Weekly Steroid Mass: 780 mg/week (comprising Testosterone Enanthate 300 mg/week + Nandrolone Phenylpropionate 240 mg/week + Methenolone Enanthate 240 mg/week; this mass sum is purely bookkeeping, excludes non-steroidal ancillaries, and does not represent a potency equivalence or safety threshold). Routine On-Cycle Support (Unlinked Ancillaries): • Human Chorionic Gonadotropin (hCG): 250 IU per administration subcutaneously 3 times weekly (Monday, Wednesday, Friday), for a per-compound weekly total of 750 IU/week, to preserve intratesticular testosterone signaling and Leydig cell sensitivity prior to PCT. • Omega-3 Fatty Acids (EPA/DHA): 3,000 mg orally once daily with a meal, for a per-compound weekly total of 21,000 mg/week, to support endothelial and lipid parameters. Conditional On-Cycle Interventions (Unlinked; Use Only If Indicated by Labs/Symptoms): • Exemestane (Aromatase Inhibitor): Do not administer prophylactically due to Primobolan's intrinsic estradiol-lowering activity. If Week 5–6 ultrasensitive estradiol ($E_2$) is elevated above reference range alongside clinical symptoms (edema, nipple tenderness), administer 6.25 mg orally on Monday/Wednesday/Friday (per-compound weekly total of 18.75 mg/week) and retest in 2–3 weeks. • Pyridoxal-5'-Phosphate (P5P / Active Vitamin B6): If mid-cycle labs reveal mild prolactin elevation, administer 50 mg orally twice daily (100 mg/day; per-compound weekly total of 700 mg/week); reserve prescription dopamine agonists (such as cabergoline 0.25 mg orally twice weekly) strictly for symptomatic, lab-confirmed hyperprolactinemia unresponsive to estradiol normalization. • Telmisartan (Angiotensin II Receptor Blocker): If resting home blood pressure consistently exceeds 130/80 mmHg despite sodium and hydration management, clinician-guided initiation of 20 mg to 40 mg orally once daily (per-compound weekly total of 140 mg to 280 mg/week) may be considered.
Administering all three oil-based compounds on the same Monday/Wednesday/Friday cadence avoids the arithmetic drift of every-other-day (EOD) schedules while satisfying NPP's requirement for frequent dosing. Draw mid-cycle bloodwork at Week 5 or 6 to assess ultrasensitive estradiol, prolactin, hematocrit, lipids, and hepatic/renal markers. Do not combine with 5-alpha-reductase inhibitors.
Anabolic-Steroid Discontinuation: • Cease all administrations of Testosterone Enanthate, Nandrolone Phenylpropionate (NPP), and Primobolan Depot (Methenolone Enanthate) after the final Friday injection of Week 12 (0 mg/week combined weekly steroid mass during Weeks 13–14). Transition Support Schedule (Unlinked Ancillaries): • Human Chorionic Gonadotropin (hCG) — Week 13 Only: Continue 250 IU per administration subcutaneously 3 times weekly (Monday, Wednesday, Friday), for a per-compound weekly total of 750 IU/week during Week 13 while exogenous steroid esters remain suppressive. • hCG Washout — Week 14: Discontinue hCG completely during Week 14 (0 IU/week) so exogenous gonadotropin stimulation and intratesticular aromatase upregulation clear for 7 days prior to starting SERM therapy in Week 15. • Omega-3 Fatty Acids (EPA/DHA) — Weeks 13–14: Continue 3,000 mg orally once daily, for a per-compound weekly total of 21,000 mg/week.
A 14-day clearance interval allows the enanthate esters (Testosterone Enanthate and Methenolone Enanthate) to decay across approximately two to three half-lives while the shorter phenylpropionate ester of NPP clears more completely before initiating hypothalamic-pituitary stimulation. Users who remain on clinician-managed testosterone replacement therapy (TRT) instead of cycling off do not execute Phases 2 through 4, and instead transition directly to their prescribed maintenance testosterone dose at Week 13.
Primary SERM Protocol (Unlinked Ancillary): • Tamoxifen Citrate (Nolvadex): 20 mg orally once daily, for a per-compound weekly total of 140 mg/week across Weeks 15–18, to antagonize hypothalamic and pituitary estrogen receptors and stimulate endogenous GnRH, LH, and FSH secretion. Continued Cardiometabolic Support (Unlinked Ancillary): • Omega-3 Fatty Acids (EPA/DHA): 3,000 mg orally once daily, for a per-compound weekly total of 21,000 mg/week. Steroid & Gonadotropin Status: • Combined Weekly Steroid Mass: 0 mg/week (no exogenous androgens, anabolic steroids, aromatase inhibitors, or hCG are administered during PCT).
Tamoxifen Citrate is specified as the primary definite schedule for this phase; in clinical and reported practice, Enclomiphene Citrate (12.5 mg orally once daily, totaling 87.5 mg/week) is frequently used as an alternative SERM where available. Because 19-norandrogens like NPP exert deep hypothalamic-pituitary suppression, PCT supports but does not guarantee rapid or complete restoration of baseline endogenous testosterone production.
Pharmacological Washout: • Discontinue Tamoxifen Citrate at the end of Week 18 (0 mg/week SERMs and 0 mg/week combined weekly steroid mass across Weeks 19–22). Baseline Supportive Nutrition (Unlinked): • Omega-3 Fatty Acids (EPA/DHA): Continue 3,000 mg orally once daily, for a per-compound weekly total of 21,000 mg/week. End-of-Phase Diagnostic Verification (End of Week 22): • Obtain a fasting morning blood panel after 4 full weeks off SERMs to evaluate true unassisted HPTA recovery (LH, FSH, Total Testosterone, Free Testosterone, SHBG, Ultrasensitive Estradiol, Prolactin) alongside complete blood count (hematocrit), comprehensive metabolic panel, and fasting lipid profile (HDL-C, LDL-C, ApoB).
Testing immediately upon finishing Tamoxifen at Week 18 can yield artificially elevated gonadotropin and testosterone readings due to residual SERM receptor occupancy (tamoxifen and its metabolites exhibit terminal half-lives of 7 to 14 days). Waiting 4 weeks post-PCT ensures lab values reflect genuine endogenous homeostasis before considering any future hormonal interventions.
Compounds in this stack
3 linked · tap for full guide
How they work together
Multipliers applied to the projection above when these compounds run together. Values > 1 indicate a bonus, < 1 a penalty.
| Pair | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.15 | ×1.00 | ×1.18 | |
| synergistic | ×1.15 | ×1.08 | ×1.10 |
Cycle outcome projection
Projection across all phases (22 weeks total) using the same math as the stack-calculator tool. Adjust gender, cycle length, and goal to see how the numbers move.
Body Transformation Preview


Lean Mass Gain
48.2 lbs
36.2–60.3 lbs range
Fat Loss
5.8 lbs
4.4–7.3 lbs range
Lean Synergy Bonus
+32%
from compound pairing
Fat Loss Synergy
+8%
from compound pairing
Per-Compound Contribution
Lean Gain by Week
Conclusion
Executing a Testosterone Enanthate, NPP, and Primobolan Depot protocol requires structured biomarker surveillance rather than fixed ancillary assumptions. Baseline, mid-cycle (Week 5–6), pre-PCT, and post-PCT laboratory panels should track ultrasensitive estradiol ($E_2$), prolactin, complete blood count (hemoglobin/hematocrit), comprehensive metabolic panel, cystatin C or eGFR, fasting lipids with ApoB, and gonadotropins (LH, FSH) alongside total and free testosterone. Because Primobolan can depress estradiol while NPP introduces progestogenic and prolactin sensitivity, both estrogen excess and estrogen deficiency must be ruled out via bloodwork before introducing conditional aromatase inhibitors or dopamine agonists. Finally, users cycling off must respect the two-week ester clearance interval prior to initiating SERM therapy and verify true endogenous recovery four weeks after PCT completion, recognizing that neither on-cycle hCG nor post-cycle SERMs guarantee full restoration of baseline neuroendocrine or cardiometabolic health.
Contraindicated & High-Risk Populations: • Female Users: This stack carries a severe risk of irreversible virilization (vocal cord thickening, hirsutism, clitoromegaly, and menstrual disruption) due to the combined androgenic exposure of Testosterone, NPP, and Primobolan. • Inexperienced / First-Cycle Users: Individuals who have not previously characterized their aromatization rate, blood pressure response, and recovery kinetics on a single-compound Testosterone cycle should avoid multi-compound 19-nor stacks. • Men Prioritizing Near-Term Fertility or Rapid HPTA Recovery: Even in phenylpropionate ester form, nandrolone metabolites exert prolonged hypothalamic-pituitary suppression that can impair spermatogenesis and delay endogenous testosterone recovery for months. • Cardiovascular, Hematologic & Renal Conditions: Individuals with established atherosclerotic cardiovascular disease, uncontrolled hypertension, severe dyslipidemia, baseline erythrocytosis/polycythemia (hematocrit >50%), history of venous thromboembolism, or chronic kidney disease. • Hormone-Sensitive Malignancies: Anyone with known or suspected carcinoma of the prostate or male breast. • Concurrent 5-Alpha-Reductase Inhibitor Users: Men taking finasteride or dutasteride, as well as individuals unwilling to accept accelerated androgenic alopecia from Methenolone Enanthate.
Updated 2026-11-17